[go: up one dir, main page]

MX2011011514A - Formulaciones de canabidiol y metodos para utilizarlas. - Google Patents

Formulaciones de canabidiol y metodos para utilizarlas.

Info

Publication number
MX2011011514A
MX2011011514A MX2011011514A MX2011011514A MX2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A MX 2011011514 A MX2011011514 A MX 2011011514A
Authority
MX
Mexico
Prior art keywords
cannabidiol
methods
same
formulations
cannabinoid
Prior art date
Application number
MX2011011514A
Other languages
English (en)
Inventor
Audra Lynn Stinchcomb
Stan Lee Banks
Original Assignee
Alltranz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltranz Inc filed Critical Alltranz Inc
Publication of MX2011011514A publication Critical patent/MX2011011514A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

Aquí se describen composiciones farmacéuticas que comprenden un canabinoide, tal como un canabidiol o un profármaco de canabidiol, el cual es metabolizado a canabidiol, y un aumentador de penetración. También se describen métodos de uso del mismo. Una modalidad aquí descrita se refiere a una administración transdérmica o tópica de las composiciones farmacéuticas que comprenden un canabinoide, tal como canabidiol o profármaco de canabidiol, y un aumentador de penetración para una persona que necesita del mismo.
MX2011011514A 2009-04-28 2010-04-28 Formulaciones de canabidiol y metodos para utilizarlas. MX2011011514A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17346909P 2009-04-28 2009-04-28
PCT/US2010/032822 WO2010127033A1 (en) 2009-04-28 2010-04-28 Formulations of cannabidiol and methods of using the same

Publications (1)

Publication Number Publication Date
MX2011011514A true MX2011011514A (es) 2011-11-18

Family

ID=42246015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011514A MX2011011514A (es) 2009-04-28 2010-04-28 Formulaciones de canabidiol y metodos para utilizarlas.

Country Status (6)

Country Link
US (1) US20100273895A1 (es)
EP (1) EP2424525A1 (es)
JP (1) JP5801794B2 (es)
CA (1) CA2760460C (es)
MX (1) MX2011011514A (es)
WO (1) WO2010127033A1 (es)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
EP3202318B1 (en) 2007-11-26 2020-10-21 C.R. Bard, Inc. Integrated system for intravascular placement of a catheter
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US9492097B2 (en) 2007-11-26 2016-11-15 C. R. Bard, Inc. Needle length determination and calibration for insertion guidance system
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
US9901714B2 (en) 2008-08-22 2018-02-27 C. R. Bard, Inc. Catheter assembly including ECG sensor and magnetic assemblies
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
US9445734B2 (en) 2009-06-12 2016-09-20 Bard Access Systems, Inc. Devices and methods for endovascular electrography
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
WO2010144922A1 (en) 2009-06-12 2010-12-16 Romedex International Srl Catheter tip positioning method
EP2482719A4 (en) 2009-09-29 2016-03-09 Bard Inc C R STYLETS FOR USE WITH APPARATUS FOR INTRAVASCULAR PLACEMENT OF A CATHETER
US10639008B2 (en) 2009-10-08 2020-05-05 C. R. Bard, Inc. Support and cover structures for an ultrasound probe head
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
BR112012019354B1 (pt) 2010-02-02 2021-09-08 C.R.Bard, Inc Método para localização de um dispositivo médico implantável
EP4122385A1 (en) 2010-05-28 2023-01-25 C. R. Bard, Inc. Insertion guidance system for needles and medical components
EP2912999B1 (en) 2010-05-28 2022-06-29 C. R. Bard, Inc. Apparatus for use with needle insertion guidance system
KR101856267B1 (ko) 2010-08-20 2018-05-09 씨. 알. 바드, 인크. Ecg-기반 카테터 팁 배치의 재확인
ES2541485T3 (es) * 2010-10-19 2015-07-21 Parenteral, A.S. Composición para el tratamiento de enfermedades inflamatorias, la cual comprende ácidos boswéllicos y cannabidiol
EP2632360A4 (en) 2010-10-29 2014-05-21 Bard Inc C R IMPROVED ASSISTED BY BIO-IMPEDANCE OF A MEDICAL DEVICE
US11344505B1 (en) * 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US12318420B2 (en) 2010-12-01 2025-06-03 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
USD724745S1 (en) 2011-08-09 2015-03-17 C. R. Bard, Inc. Cap for an ultrasound probe
JP5820207B2 (ja) * 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP5820206B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
WO2013070775A1 (en) 2011-11-07 2013-05-16 C.R. Bard, Inc Ruggedized ultrasound hydrogel insert
CN104837413B (zh) 2012-06-15 2018-09-11 C·R·巴德股份有限公司 检测超声探测器上可移除帽的装置及方法
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
ES2538335T3 (es) * 2013-05-14 2015-06-19 Najöpharm Gmbh I.G. Combinación de ácido poliacrílico y 2-amino-2-metilpropanol para uso en el tratamiento de infecciones por herpes
WO2015074137A1 (en) 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US9839372B2 (en) 2014-02-06 2017-12-12 C. R. Bard, Inc. Systems and methods for guidance and placement of an intravascular device
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
CA3111682A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
MX2017004772A (es) * 2014-07-18 2017-10-12 Medipath Inc Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
CN106794168A (zh) * 2014-07-21 2017-05-31 格利亚有限责任公司 用大麻素治疗放疗和化疗相关的认知或情感损伤的方法
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10398776B1 (en) * 2014-11-03 2019-09-03 Essential Green Goodness LLC Phonophoretic cannabidiol composition and transdermal delivery system
US20170367875A1 (en) * 2014-12-17 2017-12-28 One World Cannabis Ltd Novel condom comprising cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms
US20180020699A1 (en) * 2014-12-19 2018-01-25 Thc Pharm Gmbh The Health Concept Cbd-containing beverage
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
US20160256410A1 (en) * 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
EP3302464A4 (en) * 2015-05-27 2019-01-23 Mary Lynch USE OF CANNABINOIDS FOR THE TREATMENT OF EYE IGNITIONS AND / OR PAIN
ES2938560T3 (es) 2015-05-28 2023-04-12 Radius Pharmaceuticals Inc Formulaciones de cannabinoides estables
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
GB2544468A (en) * 2015-11-12 2017-05-24 Jaytee Biosciences Ltd Liquid formulation
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
AU2017252575B2 (en) 2016-04-22 2021-11-18 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
US20190184364A1 (en) * 2016-05-03 2019-06-20 International Flavors & Fragrances Inc. Fragrance compositions containing microcapsules
US12042479B2 (en) 2016-05-04 2024-07-23 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US20190030170A1 (en) * 2016-05-10 2019-01-31 Vireo Health LLC Cannabinoid formulations with improved solubility
CN109963595B (zh) 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
CA3042493A1 (en) * 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
JP7225104B2 (ja) 2017-02-01 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド マスト細胞関連炎症障害又は好塩基球媒介炎症障害の治療のためのカンナビノイド含有複合混合物
NZ756307A (en) * 2017-02-15 2023-01-27 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of acne
US10231948B2 (en) 2017-02-27 2019-03-19 Jason Ty Nguyen Metered dose inhaler compositions, systems, and methods
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US20190022028A1 (en) * 2017-07-21 2019-01-24 Annabelle Manalo Cannabidiol-enriched caprylic acid
CA3071497A1 (en) * 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition and method of treatment
BR112020003025A2 (pt) * 2017-08-14 2020-08-04 Zynerba Pharmaceuticals, Inc. métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
JP2020534362A (ja) 2017-09-19 2020-11-26 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
EP3684353A4 (en) * 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
RS62969B1 (sr) 2017-09-28 2022-03-31 Zynerba Pharmaceuticals Inc Lečenje fragilnog x sindroma i autizma kanabidiolom
US11738158B2 (en) 2017-10-04 2023-08-29 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device and methods of use
CN111801093A (zh) * 2017-10-17 2020-10-20 雷米生物科学公司 用于包括cbd增强的组合物、制剂和嵌合体的部分的改善的递送系统
WO2019094628A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
KR102063524B1 (ko) * 2017-11-10 2020-01-08 안용훈 칸나비디올을 포함하는 화장료 조성물
GB201720992D0 (en) * 2017-12-15 2018-01-31 Hooper Mark A medical use
CA3089360A1 (en) * 2018-01-24 2019-08-01 Botanix Pharmaceuticals Ltd Cannabinoid dosing regime for dermatitis and inflammatory skin conditions
WO2019144191A1 (en) * 2018-01-24 2019-08-01 Botanix Pharmaceuticals Ltd Cannabinoid dosing regime for psoriasis
BR112020014955A2 (pt) * 2018-01-24 2020-12-22 Botanix Pharmaceuticals Ltd Regime de dosagem de canabinoides para acne
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
MX2020011371A (es) * 2018-04-27 2021-04-12 Remy Biosciences Inc Nuevos dispositivos medicos, vehiculos de suministro y fabricacion de los mismos.
US11096904B2 (en) * 2018-05-11 2021-08-24 Linda J. Kaplan Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia
US20200009077A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Compositions for treating dermatological diseases
US10588979B1 (en) * 2018-09-17 2020-03-17 Cody D. Freeze Cannabinoid and terpene-infused topical cream
EP3852622B1 (en) 2018-10-16 2025-04-02 Bard Access Systems, Inc. Safety-equipped connection systems and methods thereof for establishing electrical connections
JP7566336B2 (ja) 2018-11-19 2024-10-15 スポーク・サイエンシズ・インコーポレイテッド カンナビノイド由来組成物の吸収変動を低減するｎ－アシル化脂肪アミノ酸
CA3122735A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US20220071922A1 (en) * 2018-12-26 2022-03-10 Clear Lake Research, Llc Delivery of health benefits through component formulation
US20220184003A1 (en) * 2019-02-06 2022-06-16 Emerald Health Pharmaceuticals Inc Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2)
IT201900003325A1 (it) * 2019-03-07 2020-09-07 C I A M S R L Composizione per la prevenzione e trattamento della dermatite atopica
US20230414492A1 (en) * 2019-04-02 2023-12-28 Nose To Brain Therapeutics Llc Intranasal delivery of cannabidiol to treat central nervous system disorders
WO2020206205A1 (en) * 2019-04-03 2020-10-08 Willow Bark Brands, Inc Dosage forms and methods of preparation and use thereof
US11806645B1 (en) 2019-05-07 2023-11-07 Cannaceutical Extractions LLC Methods of producing CBD/THC oils
US11931333B1 (en) * 2019-05-28 2024-03-19 Peter Van Horn Topical treatment of herpes infections
US12029707B2 (en) 2019-05-28 2024-07-09 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
CA3141993A1 (en) * 2019-05-28 2020-12-03 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
CN113993517A (zh) * 2019-06-18 2022-01-28 博塔尼克斯制药有限公司 使用大麻素的抗菌剂量方案
JP2022546928A (ja) * 2019-08-05 2022-11-10 シーエス メディカ アー／エス カンナビジオールを含む局所製剤、組成物の調製方法およびその使用
US20220362169A1 (en) * 2019-08-30 2022-11-17 Natural Extraction Systems, LLC Compositions and methods related to dissolved oxides
CA3150979A1 (en) 2019-09-12 2021-03-18 Nulixir Inc. Controlled release core-shell particles and suspensions including the same
BR112022004272A2 (pt) 2019-09-17 2022-06-07 Zynerba Pharmaceuticals Inc Tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimental
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
JP7670700B2 (ja) * 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
CA3156239A1 (en) 2019-10-13 2021-04-22 Figene, Llc Cannabidiol adjuvant therapy for treatment of disc degenerative disease
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
AU2020366147B2 (en) * 2019-10-14 2024-09-05 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
WO2021087291A1 (en) * 2019-10-31 2021-05-06 Natural Extraction Systems, LLC Compositions and methods related to organic oxides
CA3166011A1 (en) * 2019-12-31 2021-07-08 Soluscience, Llc Water-soluble cannabinoid formulations and methods of their making
US20230050379A1 (en) * 2020-01-20 2023-02-16 Nutramax Laboratories, Inc. Novel formulations comprising cannabis
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CA3178878A1 (en) * 2020-04-20 2021-10-28 Fotios M. Plakogiannis Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
KR20230014721A (ko) 2020-05-21 2023-01-30 엘리멘티스 스페셜티즈, 인크. 칸나비디올 및 활성제 전달 시스템
KR20230016003A (ko) 2020-05-26 2023-01-31 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료
MX2022016536A (es) 2020-06-29 2023-03-15 Zynerba Pharmaceuticals Inc Tratamiento del síndrome de x frágil con cannabidiol.
AU2021302977A1 (en) * 2020-07-01 2023-02-09 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20230131989A1 (en) * 2020-07-29 2023-04-27 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
US12349706B2 (en) 2020-07-31 2025-07-08 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
GB202012836D0 (en) * 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition
CA3201666A1 (en) 2020-11-16 2022-05-19 SYNERGY LIFE SCIENCE, Inc. Cannabinoid emulsifier
EP4255402A1 (en) 2020-12-03 2023-10-11 Zynerba Pharmaceuticals, Inc. Cannabidiol for the treatment of refractory seizures
JP2024505212A (ja) 2021-01-28 2024-02-05 ジナーバ・ファーマシューティカルズ・インコーポレイテッド Ｃｂｄを用いた睡眠時無呼吸の処置
CN116940343A (zh) 2021-02-05 2023-10-24 Cs 医学股份有限公司 关节炎和银屑病的补充剂
CA3213953A1 (en) * 2021-04-08 2022-10-13 Fotios M. Plakogiannis Pharmaceutical composition and method for treating seizure disorders
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
MX2023012483A (es) * 2021-04-22 2023-11-03 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.
DK181458B1 (en) * 2021-05-06 2024-01-31 Cs Medica As Wound treatment composition, use thereof and method for providing said composition
DK181405B1 (en) 2021-05-25 2023-10-17 Cs Medica As Gel for Intranasal Application, its Provision and Use
JP2024525200A (ja) 2021-06-22 2024-07-10 ニューマ・リスパイラトリー・インコーポレイテッド プッシュ排出を用いる液滴送達デバイス
US12064461B2 (en) * 2021-07-16 2024-08-20 Avicanna Inc. Deep penetrating topical cannabinoid compositions and methods for treating musculoskeletal inflammation and pain
US20250228876A1 (en) * 2021-10-13 2025-07-17 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
MX2024004766A (es) 2021-10-22 2024-06-11 Zynerba Pharmaceuticals Inc Tratamiento de irritabilidad en sujetos con trastornos de espectro autista con ansiedad y/o evitación social de moderada a severa.
IL312277A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Systems and methods for producing hemp extracts and compositions
IL312273A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods of treating endometrial cancer using hemp extract
MX2024005002A (es) 2021-10-26 2024-07-15 Univ Newcastle Métodos para tratar la endometriosis y otros trastornos ginecológicos no cancerosos con extracto de cáñamo.
US20230404910A1 (en) * 2022-06-16 2023-12-21 Stephanie Gore Implantable cannabis transdermal
US12161795B2 (en) 2022-07-18 2024-12-10 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method
IL320518A (en) 2022-10-26 2025-06-01 Ecofibre Usa Inc Stabilized compositions containing cannabidiol
IL320517A (en) 2022-10-26 2025-06-01 Ecofibre Usa Inc Methods for treating estrogen-sensitive diseases with cannabis extract
WO2024158861A1 (en) * 2023-01-24 2024-08-02 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
WO2024234014A1 (en) * 2023-05-11 2024-11-14 Spiritus Bioscience, Inc. Sublingual spray formulations of psychedelics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
MX2010001242A (es) * 2007-07-30 2010-07-02 Alltranz Inc Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use

Also Published As

Publication number Publication date
EP2424525A1 (en) 2012-03-07
JP2012525416A (ja) 2012-10-22
US20100273895A1 (en) 2010-10-28
WO2010127033A1 (en) 2010-11-04
JP5801794B2 (ja) 2015-10-28
CA2760460A1 (en) 2010-11-04
CA2760460C (en) 2019-04-02

Similar Documents

Publication Publication Date Title
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
MX2010001242A (es) Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
ECSP11011459A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
MY161595A (en) Oral care compositions
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
PH12012501620A1 (en) Oral care compositions
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2009007784A (es) Composiciones de tiacumicinas estables.
BR112012029739A2 (pt) polissacarídeo da semente de tamarindo para uso no tratamento de infecções microbianas
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
MX2015003074A (es) Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
GEP20135859B (en) Stable combined pharmaceutical composition
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
ES2325291A1 (es) "uso de un extracto de silybum marianum"
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms
IN2014DN10134A (es)
WO2009102375A3 (en) Use of avicins to deliver therapeutic and diagnostic agents
MX2008006476A (es) Composiciones de lipopeptidos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal